NCT05546151View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

April 7, 2023

Study Completion Date

April 7, 2023

Conditions
Healthy Participants
Interventions
DRUG

BMS-986322

Specified dose on specified days

OTHER

Placebo for BMS-986322

Specified dose on specified days

Trial Locations (1)

92801

Anaheim Clinical Trials Llc, Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT05546151 - A Study to Assess the Safety and Tolerability of BMS-986322 in Healthy Participants of Japanese Descent | Biotech Hunter | Biotech Hunter